Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia

Journal of Clinical Lipidology

Volumn 2, Issue 6, 2008, Pages 426-435

  Bays, Harold E ^a   Jones, Peter H ^b   Mohiuddin, Syed M ^c   Kelly, Maureen T ^d   Sun, Hsiaoming ^d   Setze, Carolyn M ^d   Buttler, Susan M ^d   Sleep, Darryl J ^d   Stolzenbach, James C ^d  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

Cholesterol; Dyslipidemias; Fenofibric acid; Hydroxymethylglutaryl CoA reductase inhibitors; Lipoproteins

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; FENOFIBRATE; FENOFIBRIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; TRILIPIX; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILE DUCT OBSTRUCTION; BODY MASS; BODY TEMPERATURE; BODY WEIGHT; BRAIN EDEMA; CANADA; CARDIOPULMONARY INSUFFICIENCY; CAUCASIAN; CHOLECYSTITIS; CHOLELITHIASIS; CHRONIC CHOLECYSTITIS; CIGARETTE SMOKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ETHNIC DIFFERENCE; FEMALE; HEADACHE; HEART ARREST; HEART INFARCTION; HISPANIC; HUMAN; HYPERTENSION; INTERVERTEBRAL DISK HERNIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; MULTICENTER STUDY; NEGRO; OBESITY; OSTEOARTHRITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PUERTO RICO; PULSE RATE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY ARREST; RESPIRATORY FAILURE; RHABDOMYOLYSIS; RHINOPHARYNGITIS; SIDE EFFECT; SPONTANEOUS ABORTION; SYNCOPE; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; UREA NITROGEN BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 57349155535     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2008.10.001     Document Type: Article

References (18)

1. Ellen R.L., and McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 81 (1998) 60B-65B
2. Athyros V.G., Papageorgiou A.A., Athyrou V.V., Demitriadis D.S., and Kontopoulos A.G. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 25 (2002) 1198-1202
3. Vega G.L., Ma P.T., Cater N.B., et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 91 (2003) 956-960
4. Durrington P.N., Tuomilehto J., Hamann A., Kallend D., and Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 64 (2004) 137-151
5. Grundy S.M., Vega G.L., Yuan Z., et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 95 (2005) 462-468
6. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 45 (2005) 1649-1653
7. Bays H. Statin safety: an overview and assessment of the data-2005. Am J Cardiol 97 suppl (2006) 6C-26C
8. Davidson M.H. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 5 (2006) 145-156
9. Jones P.H., and Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95 (2005) 120-122
10. Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid), in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol, in press.
11. Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis, in press.
12. Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J, in press.
13. Jones P.H., Bays H.E., Davidson M.H., et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins. Clin Drug Invest 28 (2008) 625-634
14. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
15. Jones P., Kafonek S., Laurora I., and Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81 (1998) 582-587
16. Olsson A.G. Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin Rosuvastatin. Am J Cardiol 87 suppl (2001) 33B-36B
17. Nakeeb A., Comuzzie A.G., Martin L., et al. Gallstones: genetics versus environment. Ann Surg 235 (2002) 842-849
18. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421